Albany Molecular Research (AMRI) 17.55 $AMRI
Insider Trading Alert - WLFC, KCG And AMRI Traded By Insiders
at The Street - Fri Mar 20, 10:30AM CDT
Stocks with insider trader activity include WLFC, KCG and AMRI
KCG: 12.33 (-0.11), WLFC: 18.82 (+0.33), AMRI: 17.55 (-0.01)
Insider Trading Alert - AMRI, LAD And RSE Traded By Insiders
at The Street - Tue Mar 17, 12:30PM CDT
Stocks with insider trader activity include AMRI, LAD and RSE
LAD: 99.07 (+2.40), RSE: 18.99 (-0.11), AMRI: 17.55 (-0.01)
Insider Trading Alert - PRGX, AHC And AMRI Traded By Insiders
at The Street - Fri Mar 13, 11:48AM CDT
Stocks with insider trader activity include PRGX, AHC and AMRI
AHC: 8.22 (-0.13), PRGX: 4.00 (+0.04), AMRI: 17.55 (-0.01)
5 Stocks Insiders Love Right Now
at The Street - Wed Mar 11, 7:19AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
RDUS: 43.54 (+1.77), SGEN: 36.10 (-0.12), HLX: 14.77 (+0.12), AMRI: 17.55 (-0.01), FOXF: 15.28 (+0.17)
Insider Trading Alert - AMRI, NCR And MKTX Traded By Insiders
at The Street - Mon Mar 09, 1:00PM CDT
Stocks with insider trader activity include AMRI, NCR and MKTX
MKTX: 86.47 (+2.49), NCR: 30.02 (-0.07), AMRI: 17.55 (-0.01)
InsiderInsights.com Daily Round Up 3/6/15: BK, OAS, GPC, CAPL
InsiderInsights - at Seeking Alpha - Sat Mar 07, 11:01AM CST
OCR: 77.85 (+1.05), GPC: 93.86 (+0.93), BRCM: 44.11 (+1.20), QTWO: 21.44 (+0.28), CB: 101.84 (+1.49), AMRI: 17.55 (-0.01), LKFN: 40.98 (+0.54), PCLN: 1,149.83 (+14.64), HTWO: 9.70 (-0.11), GGP: 29.98 (+0.43), ARMK: 32.10 (+0.53), CAPL: 33.30 (+0.16), ETFC: 28.24 (+0.39), TWTR: 49.89 (-0.12), BLMN: 24.28 (+0.46), GRPN: 7.43 (-0.18), BK: 40.29 (+0.54), IG: 8.45 (-0.32), OAS: 14.17 (+0.11), ALCO: 52.72 (+1.68)
Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'
M2 - Tue Mar 03, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcgwrg/the_generic_drugs) has announced the addition of SNS Research's new report "The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" to their offering. A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights. Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs. SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets. The "Generic Drugs Market: 2015 -- 2030 -- Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. Key Findings: - Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years. - As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan. - In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs. - In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia. - Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020. Key Topics Covered: Chapter 1: Introduction Chapter 2: An Overview of Generic Drugs Chapter 3: Regulatory Landscape Chapter 4: Drug Class Availability & Leading Therapies Chapter 5: Generic Drugs Industry Roadmap & Value Chain Chapter 6: Key Market Players Chapter 7: Market Analysis & Forecasts Chapter 8: Conclusion & Strategic Recommendations Companies Mentioned - ACETO Corporation - AMA (African Medicines Regulatory Agency) - AMRI (Albany Molecular Research, Inc.) - ASKA Pharmaceutical Company - AbbVie - Abbott Laboratories - Acino Holding - Actavis - Actelion - Adcock Ingram - Aesica Pharmaceuticals - Ajinomoto - Akron - Alexion Pharmaceuticals - Alfa Wasserman - Allergan - Almirall - Amgen - Amneal Pharmaceuticals - ApoPharma - Apotex - Arch Pharmalabs - Aspen Holdings - Astellas Pharma - AstraZeneca - Aurobindo Pharma - Auxilium Pharmaceuticals - BD (Becton, Dickinson and Company) - BD Rx - BMS (Bristol-Myers Squibb) For more information visit http://www.researchandmarkets.com/research/xc...eric_drugs Source: SNS Research
AGN: 240.22 (+2.88), ACET: 22.39 (+0.56), ABT: 47.08 (+0.30), AUXL: 36.47 (-0.06), ALXN: 180.26 (-0.33), AMGN: 164.30 (+1.71), BMY: 65.76 (+0.50), AMRI: 17.55 (-0.01)
Insider Trading Alert - RTEC, PFE And AMRI Traded By Insiders
at The Street - Fri Feb 13, 10:30AM CST
Stocks with insider trader activity include RTEC, PFE and AMRI
PFE: 35.00 (+0.47), RTEC: 11.19 (-0.07), AMRI: 17.55 (-0.01)
AMRI Realigns Global Operations to Enhance Continuous Supply Chain for Customers
PR Newswire Europe - Thu Feb 12, 3:01PM CST
-- Announces Key Leadership Promotions
AMRI: 17.55 (-0.01)
Albany Molecular Research's (AMRI) CEO Bill Marth on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 1:43PM CST
AMRI: 17.55 (-0.01)
Albany Molecular Research (AMRI) Q3 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 12, 7:25AM CST
AMRI: 17.55 (-0.01)
Albany Molecular Research posts 4Q loss
Automated Insights - Thu Feb 12, 7:07AM CST
ALBANY, N.Y. (AP) _ Albany Molecular Research Inc. (AMRI) on Thursday reported a fourth-quarter loss of $1.9 million, after reporting a profit in the same period a year earlier.
AMRI: 17.55 (-0.01)
Albany Molecular misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:54AM CST
AMRI: 17.55 (-0.01)
AMRI Announces Fourth Quarter and Full Year 2014 Results
PR Newswire Europe - Thu Feb 12, 6:31AM CST
-- Fourth quarter contract revenue of $80.7 million, up 35% from 2013
AMRI: 17.55 (-0.01)
AMRI Announces Proposal to Close UK-Based API Manufacturing Facility
PR Newswire Europe - Thu Feb 12, 6:31AM CST
AMRI announced today its intention, subject to consultation with its UK workforce, to close its UK facility in Holywell, Wales, which provides chemical development services and small- and large-scale manufacturing services of active pharmaceutical ingredients (API).
AMRI: 17.55 (-0.01)
5 Hated Earnings Stocks That You Should Love: Pinnacle Entertainment and More
at The Street - Tue Feb 10, 8:02AM CST
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
PNK: 35.91 (+0.01), KN: 19.25 (-0.16), CSOD: 29.27 (-0.22), BCOR: 13.80 (-0.20), AMRI: 17.55 (-0.01)
AMRI Hires Chief Information Officer
PR Newswire Europe - Mon Feb 09, 3:00PM CST
AMRI announced today that Jimmy Wang, Ph.D., fills the newly created position of Chief Information Officer, effective immediately. He replaces Carl Neumann, Senior Director, Information Technology, who retires this month.
AMRI: 17.55 (-0.01)
Insider Trading Alert - WLFC, KCG And AMRI Traded By Insiders
at The Street - Fri Mar 20, 10:30AM CDT
Stocks with insider trader activity include WLFC, KCG and AMRI
KCG: 12.33 (-0.11), WLFC: 18.82 (+0.33), AMRI: 17.55 (-0.01)
Insider Trading Alert - AMRI, LAD And RSE Traded By Insiders
at The Street - Tue Mar 17, 12:30PM CDT
Stocks with insider trader activity include AMRI, LAD and RSE
LAD: 99.07 (+2.40), RSE: 18.99 (-0.11), AMRI: 17.55 (-0.01)
Insider Trading Alert - PRGX, AHC And AMRI Traded By Insiders
at The Street - Fri Mar 13, 11:48AM CDT
Stocks with insider trader activity include PRGX, AHC and AMRI
AHC: 8.22 (-0.13), PRGX: 4.00 (+0.04), AMRI: 17.55 (-0.01)
5 Stocks Insiders Love Right Now
at The Street - Wed Mar 11, 7:19AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
RDUS: 43.54 (+1.77), SGEN: 36.10 (-0.12), HLX: 14.77 (+0.12), AMRI: 17.55 (-0.01), FOXF: 15.28 (+0.17)
Insider Trading Alert - AMRI, NCR And MKTX Traded By Insiders
at The Street - Mon Mar 09, 1:00PM CDT
Stocks with insider trader activity include AMRI, NCR and MKTX
MKTX: 86.47 (+2.49), NCR: 30.02 (-0.07), AMRI: 17.55 (-0.01)
InsiderInsights.com Daily Round Up 3/6/15: BK, OAS, GPC, CAPL
InsiderInsights - at Seeking Alpha - Sat Mar 07, 11:01AM CST
OCR: 77.85 (+1.05), GPC: 93.86 (+0.93), BRCM: 44.11 (+1.20), QTWO: 21.44 (+0.28), CB: 101.84 (+1.49), AMRI: 17.55 (-0.01), LKFN: 40.98 (+0.54), PCLN: 1,149.83 (+14.64), HTWO: 9.70 (-0.11), GGP: 29.98 (+0.43), ARMK: 32.10 (+0.53), CAPL: 33.30 (+0.16), ETFC: 28.24 (+0.39), TWTR: 49.89 (-0.12), BLMN: 24.28 (+0.46), GRPN: 7.43 (-0.18), BK: 40.29 (+0.54), IG: 8.45 (-0.32), OAS: 14.17 (+0.11), ALCO: 52.72 (+1.68)
Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'
M2 - Tue Mar 03, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcgwrg/the_generic_drugs) has announced the addition of SNS Research's new report "The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" to their offering. A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights. Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs. SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets. The "Generic Drugs Market: 2015 -- 2030 -- Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. Key Findings: - Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years. - As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan. - In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs. - In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia. - Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020. Key Topics Covered: Chapter 1: Introduction Chapter 2: An Overview of Generic Drugs Chapter 3: Regulatory Landscape Chapter 4: Drug Class Availability & Leading Therapies Chapter 5: Generic Drugs Industry Roadmap & Value Chain Chapter 6: Key Market Players Chapter 7: Market Analysis & Forecasts Chapter 8: Conclusion & Strategic Recommendations Companies Mentioned - ACETO Corporation - AMA (African Medicines Regulatory Agency) - AMRI (Albany Molecular Research, Inc.) - ASKA Pharmaceutical Company - AbbVie - Abbott Laboratories - Acino Holding - Actavis - Actelion - Adcock Ingram - Aesica Pharmaceuticals - Ajinomoto - Akron - Alexion Pharmaceuticals - Alfa Wasserman - Allergan - Almirall - Amgen - Amneal Pharmaceuticals - ApoPharma - Apotex - Arch Pharmalabs - Aspen Holdings - Astellas Pharma - AstraZeneca - Aurobindo Pharma - Auxilium Pharmaceuticals - BD (Becton, Dickinson and Company) - BD Rx - BMS (Bristol-Myers Squibb) For more information visit http://www.researchandmarkets.com/research/xc...eric_drugs Source: SNS Research
AGN: 240.22 (+2.88), ACET: 22.39 (+0.56), ABT: 47.08 (+0.30), AUXL: 36.47 (-0.06), ALXN: 180.26 (-0.33), AMGN: 164.30 (+1.71), BMY: 65.76 (+0.50), AMRI: 17.55 (-0.01)
Insider Trading Alert - RTEC, PFE And AMRI Traded By Insiders
at The Street - Fri Feb 13, 10:30AM CST
Stocks with insider trader activity include RTEC, PFE and AMRI
PFE: 35.00 (+0.47), RTEC: 11.19 (-0.07), AMRI: 17.55 (-0.01)
AMRI Realigns Global Operations to Enhance Continuous Supply Chain for Customers
PR Newswire Europe - Thu Feb 12, 3:01PM CST
-- Announces Key Leadership Promotions
AMRI: 17.55 (-0.01)
Albany Molecular Research's (AMRI) CEO Bill Marth on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 1:43PM CST
AMRI: 17.55 (-0.01)
Albany Molecular Research (AMRI) Q3 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 12, 7:25AM CST
AMRI: 17.55 (-0.01)
Albany Molecular Research posts 4Q loss
Automated Insights - Thu Feb 12, 7:07AM CST
ALBANY, N.Y. (AP) _ Albany Molecular Research Inc. (AMRI) on Thursday reported a fourth-quarter loss of $1.9 million, after reporting a profit in the same period a year earlier.
AMRI: 17.55 (-0.01)
Albany Molecular misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:54AM CST
AMRI: 17.55 (-0.01)
AMRI Announces Fourth Quarter and Full Year 2014 Results
PR Newswire Europe - Thu Feb 12, 6:31AM CST
-- Fourth quarter contract revenue of $80.7 million, up 35% from 2013
AMRI: 17.55 (-0.01)
AMRI Announces Proposal to Close UK-Based API Manufacturing Facility
PR Newswire Europe - Thu Feb 12, 6:31AM CST
AMRI announced today its intention, subject to consultation with its UK workforce, to close its UK facility in Holywell, Wales, which provides chemical development services and small- and large-scale manufacturing services of active pharmaceutical ingredients (API).
AMRI: 17.55 (-0.01)
5 Hated Earnings Stocks That You Should Love: Pinnacle Entertainment and More
at The Street - Tue Feb 10, 8:02AM CST
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
PNK: 35.91 (+0.01), KN: 19.25 (-0.16), CSOD: 29.27 (-0.22), BCOR: 13.80 (-0.20), AMRI: 17.55 (-0.01)
AMRI Hires Chief Information Officer
PR Newswire Europe - Mon Feb 09, 3:00PM CST
AMRI announced today that Jimmy Wang, Ph.D., fills the newly created position of Chief Information Officer, effective immediately. He replaces Carl Neumann, Senior Director, Information Technology, who retires this month.
AMRI: 17.55 (-0.01)
